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Life-threatening ventricular arrhythmias (VA) are a major cause of death in patients with
cardiomyopathy. To date, impaired left ventricular ejection fraction remains the primary
criterion for implantable cardioverter-defibrillator therapy to prevent sudden cardiac death. In
recent years, however, advanced imaging techniques such as nuclear imaging, cardiac magnetic
resonance imaging, and computed tomography have allowed for a more detailed evaluation of
the underlying substrate of VA. These imaging modalities have emerged as a promising
approach to assess the risk of sudden cardiac death. In addition, non-invasive identification of
the critical sites of arrhythmias may guide ablation therapy. Typical anatomical substrates that
can be evaluated by multiple advanced imaging techniques include perfusion abnormalities,
scar and its border zone, and sympathetic denervation. Understanding the principles and
techniques of different imaging modalities is essential to gain more insight in their role in
identifying the arrhythmic substrate. The current review describes the principles of currently
available imaging techniques to identify the substrate of VA.
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Sudden cardiac death (SCD) is a major health
problem as it accounts for half of total cardiac mortality
with an annual incidence of approximately 100 per
100.000 in the general population.1,2 In most cases, SCD
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is caused by ventricular arrhythmia (VA) in patients who
suffer from underlying structural heart disease including
ischemic cardiomyopathy, dilated cardiomyopathy, and
hypertrophic cardiomyopathy.1 Implantable car-
dioverter-defibrillators (ICDs) have led to a significant
reduction in mortality and have become standard clinical
practice for the primary prevention of SCD in patients
with left ventricular ejection fraction (LVEF)\30-35%,
depending on cardiomyopathy etiology and heart failure
symptoms.3-5 There are, however, several downsides of
patient selection according to LVEF only. Recent
studies have revealed that only 11-35% of patients with
ICDs implanted for primary prevention of SCD actually
receive appropriate ICD therapy in the ensuing years.6-8
It is clear that impairment of global LVEF is merely an
indirect and aspecific risk factor for SCD, which is
actually the result of underlying structural abnormalities
causing electrical instability. A more detailed evaluation
of the anatomical substrate of arrhythmias has therefore
been an emerging topic of research over the last decade.
Advanced cardiac imaging modalities such as nuclear
imaging, cardiac magnetic resonance (CMR) imaging,
and computed tomography (CT) hold great promise in
evaluating the arrhythmic substrate to enhance risk
stratification.9-11 More recently, these imaging modali-
ties have also been used to identify critical sites of
ventricular tachycardia (VT) in order to guide electro-
physiological ablation therapy.12-17 It is therefore
important to understand the principles of these imaging
techniques used to identify the arrhythmic substrate.
This review discusses the principles and techniques of
currently available advanced imaging techniques in
identifying the substrate for ventricular arrhythmias.
IMAGING TARGETS OF THE ARRHYTHMIC
SUBSTRATE
The pathophysiology of VA is complex and mul-
tifactorial. Traditionally, they are believed to be the
result of a complex interplay between an anatomical
substrate and transient triggers leading to electrical
instability including increased automaticity, triggered
activity, and re-entry.18 In more than 75% of SCD cases
in the Western world, ischemic heart disease is respon-
sible for the underlying arrhythmic substrate.1 Frequent
culprits of susceptibility for VA are the presence of
myocardial ischemia, scar burden, and sympathetic
denervation.19 Various non-invasive imaging modalities
have the potential to target these pathophysiological
processes (Figure 1). Perfusion abnormalities may
induce ischemia during an acute coronary syndrome or
in the setting of chronic ischemic heart disease. In both
scenarios, variations in myocardial perfusion may result
in phases of ischemia and reperfusion which are
associated with triggered activity and re-entry.19-21 The
relation between ischemia and VA has been demon-
strated in clinical studies.22,23 Nuclear imaging and
CMR are considered to be the mainstay in perfusion
imaging and therefore can be performed to identify the
role of ischemia in the VA substrate. After myocardial
infarction, inexcitable scar tissue is formed, surrounded
by a border zone area with a mixture of viable myocytes
and non-viable fibrous tissue. Consequently, this area
comprises the fundamentals of a re-entry arrhythmia;
heterogeneous prolonged conduction within the border
zone adjacent to non-conduction scar tissue.24,25 This
well-known theory has been supported by clinical
studies demonstrating the association between the extent
of scarring and susceptibility for VA.26 In fact, the
infarct borderzone is generally considered as the pivotal
part of the re-entry circuit.27 Furthermore, residual
perfusion abnormalities in the infarct border zone may
contribute to the arrhythmic vulnerability.28 Late
gadolinium enhanced (LGE)-CMR is the preferred
modality for scar and border zone visualization with
high spatial resolution. Myocardial infarction does not
merely result in a loss of myocytes but causes injury of
cardiac sympathetic nerves to an even greater extent as
nerve endings are more vulnerable to ischemia.29 Areas
of denervated but viable myocardium are characterized
by prolonged refractory periods and supersensitivity to
catecholamines that cause increased heterogeneity in
repolarization.30-33 Localized regions of hyperinnerva-
tion (nerve sprouting) due to increased heterogeneous
post-injury regeneration have been observed in areas
surrounding scar, which may further augment the
electrical instability.34,35 Nuclear imaging is able to
visualize cardiac sympathetic nerve function to assess
the role of cardiac denervation. Finally, extensive
scarring can initiate structural remodelling of the left
ventricle (LV) resulting in loss of function, geometrical
alterations, and increased wall stress. These structural
changes itself have pro-arrhythmogenic effects due to
modulation of action potential duration, calcium han-
dling, and conduction.36,37
NUCLEAR IMAGING
Nuclear imaging provides the unique ability to
target different pathophysiological aspects of the
arrhythmic substrate, depending on the biological path-
way of the utilized tracer. Consequently, nuclear
techniques such as single photon emission computed
tomography (SPECT) and positron emission tomogra-
phy (PET) allow the evaluation of perfusion, scar,
metabolism, and sympathetic innervation (Figure 2).
Aspects of SPECT and PET techniques and image
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analysis with regard to the evaluation of the arrhythmic
substrate are discussed below.
Myocardial Perfusion Imaging
To date, the most widely used nuclear imaging
technique to evaluate the extent and location of myocar-
dial perfusion abnormalities is SPECT. Frequently used
SPECT tracers in clinical practice include 201TI,
[99mTc]tetrofosmin, and [99mTc]sestamibi. Based on
relative tracer uptake in the myocardium during resting
conditions and exercise or pharmacologically induced
stress, information is obtained on the size of resting
perfusion defects (reflecting scar or hibernating myo-
cardium), stress perfusion defects (reflecting scar,
hibernating myocardium and/or ischemia), and their
reversibility (reflecting ischemia).38,39 Observational
studies have demonstrated that the inducibility of VA
during an electrophysiological study is related to the
presence and size of resting perfusion defects in patients
with ischemic cardiomyopathy.40,41 Moreover, inducible
VTs were found to originate close to the border of
resting perfusion defects as observed by McFarland
et al,42 highlighting the importance of infarct border
zone. These results were confirmed in a recent study by
Tian et a15 who reconstructed 3D scar models obtained
Figure 1. Imaging targets of the potential arrhythmic substrate in two patients with ischemic
cardiomyopathy who were referred for ICD implantation for primary prevention of sudden cardiac
death. [15O]H2O PET, [
11C]HED PET, and LGE-CMR of patient 1 (A-C) displayed a basal inferior
wall myocardial infarction with contrast enhancement in this region (A) and a corresponding
perfusion defect (C) with a large innervation defect (B) that exceeded the infarct size, resulting in a
significant innervation-perfusion mismatch. Patient 2 (D-F) showed a large inferior wall myocardial
infarction with transmural contrast enhancement as well as subendocardial contrast enhancement at
the anterolateral wall (D) at LGE-CMR. [15O]H2O PET and [
11C]HED PET displayed
corresponding perfusion and innervation defects with only limited innervation-perfusion mismatch.
CMR, cardiovascular magnetic resonance; LGE, late gadolinium enhancement; PET, positron
emission tomography.
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from 201TI SPECT to identify voltage-defined scar,
border zone, and normal myocardium during elec-
troanatomic mapping in order to guide VT ablations. It
was demonstrated that impairment of 201TI uptake could
accurately predict endocardial voltage-defined scar,
which was the site of successful ablation in all patients
(Figure 3). Most critical sites of VT were located within
1 cm of the SPECT assessed scar border, although the
degree of 201TI uptake was not able to distinguish
voltage defined scar and border zone. This may be the
result of the relatively low spatial resolution of SPECT,
limiting its value in border zone assessment. Nonethe-
less, a more recent retrospective analysis by Zhou
et al,43 proposed a novel method of scar border zone
evaluation using 99mTc SPECT by calculating the size of
myocardium with uptake between 40% and 60% of peak
myocardial uptake surrounding the scar core area
(defined as\40% of peak uptake) after comparing with
template scans of healthy control patients. Interestingly,
SPECT assessed border zone was shown to be signif-
icantly larger in patients who showed inducible
sustained VA during an electrophysiological study as
compared with non-inducible patients. The study, how-
ever, did not assess the site of origin of the induced
VAs.43 Further studies are needed to evaluate the role of
SPECT assessed border zone in identifying the arrhyth-
mic substrate.
Residual ischemia after myocardial infarction may
contribute to the electrical instability of the myocar-
dium. This was revealed in a study by Paganelli et al44
who found a significant relation between the inducibility
of VA and the presence and extent of residual ischemia
as evaluated by stress-rest 201TI SPECT, in particular
within the infarct area. No differences in fixed perfusion
defects were observed, suggesting that residual ischemia
might lead to additional vulnerability to VA.
For detecting perfusion abnormalities, PET pro-
vides advantages over SPECT including higher spatial
resolution and the ability of absolute quantification of
myocardial blood flow (MBF). Furthermore, commonly
used PET perfusion tracers such as [15O]H2O,
[13N]NH3, and
82Rb have a higher extraction fraction
Figure 2. Examples of PET assessed perfusion, sympathetic innervation, and metabolism using
different PET tracers in two patients with ischemic cardiomyopathy who were referred for primary
prevention ICD therapy. (A) PET imaging revealed a mismatch between defects of perfusion and
viability (infarct size), reflecting hibernating myocardium, as well as a mismatch between
sympathetic innervation defect and infarct size, reflecting denervated but viable myocardium. This
patient experienced appropriate ICD discharge for a fast ventricular tachyarrhythmia in follow-up.
(B) PET imaging revealed matched defects of perfusion, viability, and sympathetic innervation.
ANT, anterior; ICD, implantable cardioverter-defibrillator; INF, inferior; LAT, lateral; PET, positron
emission tomography; SEP, septum. Reprint with permission.63
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and short physical half-life.45 As a result, more subtle
regional perfusion abnormalities can be detected and
quantified in mLmin-1g-1. Of the available PET
tracers, [15O]H2O is considered the most ideal tracer
for flow quantification as it is freely diffusible and
metabolically inert with an extraction of 100% from
arterial blood, whereas 82Rb and [13N]NH3 are actively
transported across the cell membrane with incomplete
extraction and subsequently are metabolically trapped.46
Consequently, [15O]H2O PET quantifies MBF in viable
tissue which is capable of exchanging water rapidly.47-49
This unique tracer characteristic might especially be of
interest to assess subtle perfusion abnormalities in small
areas of viable tissue within the infarct and border zone
area which could provide more insight into the substrate
and potential triggers of VA. A recently published pilot
study demonstrated that impaired global hyperemic
perfusion and coronary flow reserve as quantified by
[15O]H2O PET were significantly related with VA
inducibility during an electrophysiological study in 30
patients with ischemic cardiomyopathy who were
referred for ICD implantation (Figure 4).28 These results
need to be confirmed in larger studies to assess the
relation between quantitative PET perfusion imaging
and the VA substrate.
Myocardial Metabolism
Nuclear metabolic imaging to evaluate myocardial
viability is commonly assessed using [18F]fluo-
rodeoxyglucose (FDG) PET in clinical practice.
[18F]FDG is a glucose analogue which is taken up into
the cardiomyocytes by glucose transporters and subse-
quently become trapped after being metabolized.
Preserved [18F]FDG uptake is considered a highly
reliable marker for viable myocardium in patients with
ischemic heart disease whereas severely reduced
[18F]FDG uptake indicates non-viable scar tissue.50
The assessment of scar tissue using [18F]FDG PET is
well validated51,52 and good correlations have been
observed with LGE-CMR assessed fibrosis53,54 (Fig-
ure 5). As such, it provides a valid approach to visualize
the size and location of non-viable scar in order to
evaluate the site of the arrhythmic substrate although it
has not been studied frequently for this purpose.
Nonetheless, a study performed by Dickfeld et al16
demonstrated that 3D scar maps as assessed using hybrid
[18F]FDG PET/CT fusion imaging could be integrated
into clinical mapping system to visualize the 3D
arrhythmogenic substrate in patients who were referred
for VT ablation. A cut-off value of \50% [18F]FDG
activity predicted voltage defined myocardial scar with a
sensitivity and specificity of 89 and 93%, respectively,
whereas voltage defined infarct borderzone contained a
mean metabolic activity of 67±15%. These results imply
that scar evaluation with [18F]FDG PET is able to
identify critical arrhythmogenic substrates and may
assist VT ablation therapies.55,56
When combined with perfusion imaging, viable
myocardium can be further differentiated into the
presence of subendocardial scar (mildly reduced
[18F]FDG uptake and perfusion), hibernation (enhanced
[18F]FDG uptake but impaired perfusion), and normal
viable myocardium (preserved [18F]FDG and perfusion).
Figure 3. Example of 201TI SPECT assessed perfusion polar map (A) and corresponding
electroanatomic voltage map (B) in a patient with ischemic cardiomyopathy. (A) SPECT polar map
demonstrates anteroseptal and apical perfusion deficit which corresponded with the anteroseptal
low-voltage scar area (red) as revealed by the corresponding voltage map (B). SPECT, single-
photon emission computed tomography. Reprint with permission.15
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The detection of increased uptake in hibernating
myocardium is based on a metabolic shift from fatty
acid to glucose consumption as the myocytes are
hypoperfused and become dependent on anaerobic
metabolism.57 Chronic repetitive ischemia in hibernat-
ing myocardium may lead to electrical remodeling due
to adaptive responses of the myocytes which can
contribute to VA susceptibility.58 Preclinical studies
suggest that this process consists of cellular hypertrophy,
altered calcium handling, and prolongation of action
potentials leading to triggered activity and heteroge-
neous repolarization.58-61 Clinical studies, however,
Figure 4. Examples of [15O]H2O PET and LGE-CMR scan in two patients with a history of an
anterior wall myocardial infarction. Both patients displayed significant scar size (C, D, G, and H)
and perfusion defect (A, B, E and F) in the anteroseptal wall. However, quantitative MBF results
showed significantly impaired hyperemic MBF in patient 2 as compared with patient 1. Note the
difference in scaling on the PET images (A, B, E, and F) between both patients. Electrophys-
iological study showed no inducible ventricular arrhythmias in patient 1 (A-D) whereas in patient 2
(E-H) a monomorphic ventricular tachycardia was induced. CMR, cardiovascular magnetic
resonance; LGE, late gadolinium enhancement; MBF, myocardial blood flow; PET, positron
emission tomography. Reprint with permission.28
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have reported inconsistent results linking the amount of
hibernation to the actual occurrence of VA in follow-
up.62,63
Sympathetic Innervation
Targeting the cardiac sympathetic innervation using
nuclear imaging has become an emerging approach to
visualize the VA substrate. As discussed, the sympa-
thetic nervous system may give rise to VA in several
pathophysiological pathways including increased global
sympathetic activity and regional cardiac sympathetic
denervation resulting from ischemia, hibernation, or
infarction.64 The mainstay of innervation imaging is
based on the uptake, storage, and release of nore-
pinephrine (NE), which is mediated by presynaptic
sympathetic nerve terminals in response to variations of
sympathetic drive. The sympathetic neurotransmitter NE
is produced within sympathetic nerve terminals and
stored in vesicles. After sympathetic activation, it is
released into the sympathetic nerve cleft where it is able
to bind on beta-adrenergic receptors of myocytes to
Figure 5. Example of [18F]FDG PET and LGE-CMR in a patient with a posterolateral myocardial
infarction. The [18F]FDG PET images (A-G, base to apex) revealed a defect in the posterolateral
wall extending to the inferior wall at the midventricular level. LGE-CMR (1-8, base to apex) shows
transmural enhancement of a similar size in the same location. CMR, cardiovascular magnetic
resonance; LGE, late gadolinium enhancement; PET, positron emission tomography. Reprint with
permission.53
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transmit their sympathetic effects.65 Most of the NE,
however, is cleared from the synaptic cleft, either by
presynaptic neuronal re-uptake (uptake-1 mechanism), or
by non-neuronal uptake by post synaptic transporters on
myocytes (uptake-2 mechanism).66,67 After presynaptic
re-uptake, NE is metabolized or stored back into the
vesicles. Dependent on specific characteristics of the
tracer used, several biological aspects of the neuronal
function can be visualized. To date, most commonly used
tracers are NE analogues [123I]metaiodobenzylguanide
(MIBG) for SPECT and [11C]hydroxyephedrine (HED)
for PET. Both tracers are resistant to metabolic enzymes
and show high affinity for presynaptic NE uptake-1
allowing the visualization of presynaptic sympathetic
nerve function.65,68Other presynaptic PET tracers include
[11C]epinephrine, [11C]phenylephrine, and 18F-LMI1195
while [11C]-CGP12177 is the most commonly used tracer
for postsynaptic beta-adrenergic receptors.65,69
[123I]MIBG SPECT typically includes the assess-
ment of early and delayed planar as well as tomographic
images at 15-30 minutes and 3-4 hours after tracer
injection, respectively. In planar images, global myocar-
dial uptake is evaluated by calculating the heart to
mediastinum (H/M) uptake ratio. Furthermore,
[123I]MIBG washout rate (WR) is defined as the differ-
ence between the early and delayed H/M ratios and
primarily reflects presynaptic NE turnover, a marker for
sympathetic activity (Figure 6).70 In patients with car-
diomyopathy, increased sympathetic drive causing high
nerve firings and insufficient re-uptake is reflected by a
decrease in delayed H/M ratio and increased WR.68
Assessment of size and location of regional innervation
defects on tomographic delayed [123I]MIBG images
allow more detailed evaluation of the anatomic sub-
strate. Accordingly, Klein et al17 recently acquired 3D
reconstructions of [123I]MIBG SPECT and combined
these innervation maps with endocardial voltage maps as
assessed during electrophysiological study in patients
with ischemic cardiomyopathy who were referred for
VT ablation. Areas of cardiac denervation were found to
be significantly larger as compared with voltage defined
scar reflecting the higher vulnerability of cardiac nerves
Figure 6. Example of global [123I]MIBG H/M ratio and wash-out rate calculation on planar
[123I]MIBG imaging (A), and examples of normal cardiac [123I]MIBG activity in a patient with H/
M ratio of 1.80 (B) compared with a [123I]MIBG scan showing a significantly impaired [123I]MIBG
activity with H/M ratio of 1.10 (C). H/M, heart-to-mediastinum. Reprint with permission.70
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to ischemia. More importantly, all successful ablation
sites were located in myocardium with abnormal
[123I]MIBG uptake whereas in 36% these sites were
found in normal myocardium when assessed with
voltage mapping. These results indicate the role of
sympathetic denervation as VA substrate, which may be
more important than scar. When combined with SPECT
perfusion imaging, regional areas of viable but dener-
vated myocardium can be detected which are potential
sites of electrical instability.71 In a pilot study, Bax and
colleagues performed [123I]MIBG and [99mTc]tetrofos-
min SPECT in patients with ischemic cardiomyopathy
who underwent electrophysiological testing. Patients
with inducible VA showed larger areas of [123I]MIBG
defects obtained from delayed SPECT images. The
mismatch size, however, between innervation and per-
fusion defects was not related to VA susceptibility.72 As
areas of denervated but viable myocardium may be
intertwined with the infarct border zone which often
contains critical sites of VA, the assessment of
[123I]MIBG uptake in this area specifically may be of
interest. Accordingly, in a post-hoc analysis of the
previous mentioned study by Bax et al,[123I]MIBG
uptake in the infarct border zone defined using
[99mTc]tetrofosmin SPECT predicted the inducibility
of sustained VA during electrophysiological testing with
higher accuracy compared with scar or scar border zone
itself.43
The assessment of sympathetic innervation using
PET may have incremental value in evaluating the
arrhythmic substrate. First, the superior spatial resolu-
tion of PET results in more detailed assessment of
regional sympathetic innervation and innervation/perfu-
sion mismatch areas. Second, dynamic imaging
protocols enables absolute quantification of sympathetic
nerve retention of tracers.73 Third, the availability of
multiple tracers, each acting on different biological
aspects of the nerve terminals or beta-adrenergic recep-
tors, provides further insight into the cardiac neuronal
function.74 The [11C]HED PET protocol typically con-
sists of a dynamic scan with a duration of 40-60 minutes
after injection of the tracer. Subsequently, sympathetic
nerve uptake is frequently quantified using the retention
index, which is defined as the uptake in the final frame
Figure 7. Electrophysiological study in an animal with inducible VT. PET assessed perfusion and
innervation polarmaps demonstrated an innervation defect (blue) which exceeded the size of the
perfusion defect (white), predominantly in the distal anterior wall segment (bottom right). Three-
dimensional electroanatomic voltage maps (top right) demonstrated reduced voltage in apex and
distal anterior septal wall and propagation map showed earliest activation of the VT in the infarct
border zone in the distal anterior wall (red arrow), which corresponded with the location of the
innervation-perfusion mismatch. PET, positron emission tomography; VT, ventricular tachycardia.
Reprint with permission.78
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of the scan divided by the integral of the arterial input
curve.75 In addition, kinetic modelling of the tracer may
be performed which results in more absolute quantifi-
cation of the volume of distribution of the tracer and its
wash-out.73 Although [11C]HED retention, washout and
defect size are closely related to [123I]MIBG SPECT
variables, the ability of quantification may overcome
problems with relative defect size calculations such as
global downregulation in patients with heart failure.76 In
addition, by calculating the influx rate (K1) of
[11C]HED, Harms et al recently demonstrated the
feasibility of assessing perfusion and innervation defects
to evaluate mismatch areas using a single dynamic
[11C]HED PET scan.77 Several studies have showed
altered electrophysiological characteristics within areas
of reduced [11C]HED uptake including prolonged
refractoriness and supersensitivity to cate-
cholamines.30,33 Sasano et al78 showed that the extent
of viable but denervated myocardium quantified with
[11C]epinephrine and [13N]NH3 PET was associated
with inducible VTs in a porcine model. Importantly, the
area of denervated but viable myocardium was related to
the site of initiation of the induced VTs as well as
decreased endocardial voltage obtained by voltage
mapping (Figure 7). Recently, the uptake of multiple
presynaptic tracers was explored in viable but dever-
vated myocardium in a similar porcine myocardial
infarction model.79 While [11C]epinephrine retention
was impaired in the infarct border zone, [11C]HED
retention was relatively preserved, suggesting
compromised vesicular storage rather than impaired
uptake or complete denervation (Figure 8). In fact,
immunohistology of explanted hearts showed intact
nerve fibers and nerve sprouting in the infarct border
zone.79 However, results from the PAREPET study
confirmed the presence of larger [11C]HED assessed
denervation areas as compared to perfusion defects in
patients with ischemic cardiomyopathy, which may
reflect a more advance state of neuronal impairment in
chronic ischemic heart disease.63 Next to injured presy-
naptic sympathetic nerves, patients with ischemic
cardiomyopathy show abnormalities of the postsynaptic
beta-adrenergic receptors, although to a lesser extent
(Figure 9). Consequently, a mismatch between presy-
naptic and postsynaptic adrenergic signaling is present
which might be vulnerable to arrhythmias due to locally
increased levels of catecholamines affecting repolariza-
tion.80. Finally, abnormal [11C]HED retention has been
observed in non-ischemic cardiomyopathies81-83 as well
as primary arrhythmogenic disorders.84-86
CARDIAC MAGNETIC RESONANCE IMAGING
CMR imaging is increasingly used in daily clinical
practice to quantify left ventricular volumes and func-
tion. Due to superior accuracy and reproducibility, CMR
is considered as gold standard for the evaluation of LV
dimensions.87 Furthermore, 3D evaluation of LV geom-
etry may provide insight in remodelling and regional
wall stress, which is linked to VA.88 In addition, contrast
Figure 8. PET assessment of myocardial innervation using multiple radiolabeled catecholamine
analogues in an animal with myocardial infarction. (A) Polar maps of representative infarct animal
showing retention of 4 tracers (top), along with color-coded defect areas. Epinephrine and
phenylephrine defects exceeded the perfusion defect, whereas hydroxyephedrine defect is
comparable to the perfusion defect. (B) Bar chart showing group results of defect sizes. Ant,
anterior; EPI, epinephrine; HED, hydroxyephedrine; Inf, inferior; Lat, lateral; metab., metabolic;
NH3, ammonia; PET, positron emission tomography; PHEN, phenylephrine; sep, septal. Reprint
with permission.79
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agents such as gadolinium enables qualitative and semi-
quantitative assessment of perfusion based on the wash-
in of the contrast agent into the myocardium. By
comparing first-pass perfusion during pharmacologically
induced stress and resting conditions, ischemia can be
detected. However, no studies have evaluated the role of
CMR perfusion imaging in identifying the substrate of
VA to date. The actual superior value of CMR in
identifying the arrhythmic substrate is the ability of scar
tissue characterization using LGE which will be dis-
cussed below.
Late Gadolinium Enhancement
The visualization of fibrotic tissue is based on
alterations of T1 relaxation characteristics after intra-
venous contrast administration. Gadolinium diffuses out
of the intravascular volume and after 10-15 minutes it is
distributed within the extracellular tissue as it cannot
enter the myocytes. Hence, magnetic characteristics in
fibrotic tissue are altered resulting in a relatively higher
signal intensity (SI), visible as bright areas when
compared to the normal remote myocardium on the
T1-weighted images.89 Scar tissue assessment using
LGE-CMR has a high spatial resolution and is well
validated in histopathologic studies.90,91 LGE can be
quantified in absolute grams of scar tissue using the full-
with-at-half-maximum which defines scar core tissue as
SI [50% of maximum SI in hyperenhanced area, or
using different SD thresholds ([3-5 SD) of the mean SI
in remote myocardium.92 In addition, areas of interme-
diate enhancement (‘the gray zone’) can be assessed
separately using various SI thresholds such as 35-50% of
maximum SI or 2-3 SD of mean remote SI to evaluate
the scar border zone which contains a heterogeneity
of viable and non-viable tissue39,93 These different
methodologies of quantification will result in signifi-
cantly different absolute grams of scar core and scar
border zone as demonstrated in Figure 10, although all
seem related to the VA substrate.94,95 Bello et al26 was
the first to describe the association between LGE-CMR
assessed total scar size and inducibility of sustained VA
in patients with ischemic cardiomyopathy. Subse-
quently, Schmidt et al96 reported that quantification of
the heterogeneous scar size resulted in improved pre-
diction of VT inducibility. In addition, the presence of
nonischemic fibrosis is associated with VT inducibility
in patients with dilated cardiomyopathy.97 Although
these studies suggest a direct link between LGE scar
characteristics and the arrhythmogenic substrate, they
did not compare the location of scar or borderzone and
the site of origin of the induced VA. This was explored
in detail by more recent studies who evaluated patients
that underwent VT ablation. Comparable to the
described PET and SPECT studies, 3D reconstructions
of LGE-CMR assessed scar can be integrated into
electroanatomic mapping systems to visualize the
arrhythmic substrate which may assist VT ablation
strategies.12,13,98-103 For this purpose, LGE-CMR might
be superior compared with other investigated imaging
Figure 9. PET imaging of presynaptic sympathetic nerves using [11C]HED and postsynaptic beta-
adrenergic receptors using [11C]CGP12177 in a patient with ischemic cardiomyopathy. White
arrows indicate extensive mismatch between presynaptic innervation and postsynaptic beta-
adrenergic receptors in the lateral wall. HED, hydroxyephedrine; PET, positron emission
tomography. Reprint with permission.80
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modalities as it is able to discriminate between endo-
cardial, midwall, and epicardial scar localizations,
whereas invasive electroanatomic mapping only evalu-
ates the endocardial or epicardial surface.104 By
projecting the SI, transmural extension, or localization
of scar acquired from consecutive LGE cine images onto
3D shells of the LV with coloured scales, 3D LGE maps
are generated. Integration of 3D LGE with elec-
troanatomic maps provide unique insight into LGE
characteristics of critical sites of the VT. Desjardins
et al101 showed that critical sites of postinfarction VT
are located within areas of high contrast enhancement as
assessed with LGE-CMR. In addition, Perez-David
et al102 demonstrated that patients with ischemic heart
disease and documented sustained VT frequently show
continuous tissue corridors of border zone areas inside
scar tissue on 3D endocardial SI maps (Figure 11). More
importantly, these heterogeneous tissue corridors corre-
sponded with the size and location of slow conduction
channels as observed during voltage mapping and often
were the critical isthmus site of VT. In another study
using high resolution 3T LGE-CMR, 74% of the critical
isthmus sites of VTs were identified by border zone
channels which were more commonly seen in the
endocardium.98 Other studies that integrated LGE-
CMR in electroanatomic mapping demonstrated that
critical sites of the VT circuit are often located very
close to scar tissue with high transmural extension and/
or near the transition of scar core and border
zone.12,99,100,104 The described studies provide evidence
for the relation of LGE-CMR assessed scar character-
istics and the VA substrate, in particular the location of
infarct border zone and more transmurally extended scar
tissue. Finally, a preclinical study performed by Ng
et al105 showed the potential of performing a non-
invasive virtual electrophysiological study in an in-vivo
3D LGE-CMR model using a computer simulation after
applying a mathematical model that predicts VT circuits.
It was demonstrated that most of the virtually induced
VTs using CMR corresponded with actual inducible
VTs during invasive electrophysiological study.
T1 Mapping
Several limitations of LGE-CMR should be
acknowledged. First, standardization of imaging proto-
cols and analyses is lacking as different SI thresholds are
used for scar and border zone definitions. Second, LGE
is based on relative differences in SI between fibrotic
tissue and supposedly normal myocardium. Conse-
quently, LGE is only able to detect focal areas of
fibrotic tissue, whereas diffuse interstitial fibrosis cannot
be identified. The occurrence of diffuse interstitial
fibrosis, however, is not an infrequent pathological
phenomenon in cardiomyopathy, not merely in nonis-
chemic etiologies, but also in ‘remote’ areas of ischemic
cardiomyopathy.106-109 More importantly, interstitial
fibrosis may affect electrical propagation between
myocytes due to alterations in cell-coupling, thereby
contributing to the arrhythmic substrate.110 T1 mapping
Figure 10. (A) Example of short and long axis LGE-CMR images in a patient with a large anterior
wall myocardial infarction with contrast enhancement visible in the anteroseptal, anterior, and
anterolateral wall. (B) Examples of several previously validated quantification methods of the scar
core area (red) and scar border zone area (yellow), each resulting in significant a different scar core
and border zone size.
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has emerged as a new CMR technique to evaluate
diffuse fibrosis as it provides a pixel-wise quantification
of myocardial T1 values, thereby overcoming the
limitations of LGE-CMR. By quantifying absolute
native pre-contrast T1 as well as post-contrast T1
values, the extracellular volume index can be calculated
which is closely correlated with histopathologic mea-
sures of diffuse fibrosis.106,108 Although it has recently
been demonstrated that absolute T1 values may be
linked to the occurrence of VA in ischemic and non-
ischemic cardiomyopathy, future studies are needed to
confirm the role of diffuse fibrosis as assessed with T1
mapping in identifying the VA substrate111
COMPUTED TOMOGRAPHY
Contrast enhanced CT is an alternative modality for
scar evaluation with high spatial and temporal resolu-
tion. Comparable to LGE-CMR, late enhancement CT
can be acquired approximately 10 minutes after contrast
injection with a standard single-energy or dual-energy
cardiac CT. Both have been demonstrated to correlate
well with LGE-CMR assessed scar as well as
histopathologic findings112-115 In addition, perfusion
defects obtained from qualitative first-pass CT perfusion
imaging may provide information on the extent and
location of scar. Few studies have assessed the role of
contrast enhanced CT in identifying the arrhythmic
substrate. Tian et al14 evaluated abnormalities in LV wall
thickness, wall thickening, and perfusion using 3D
contrast enhanced CT in 11 patients with ischemic
cardiomyopathy who underwent VT ablation. Although
all were related with abnormal endocardial voltage
obtained from electroanatomic mapping, areas of CT
hypoperfusion showed superior correlations with scar
and border zone and represented the site of successful
ablation in 82% of cases. It has been demonstrated that
the size of both CT early hypoperfused and late hyper-
enhanced areas are comparable to LGE-CMR assessed
scar size.113,116 Consequently, contrast enhanced CT
may be used to identify the arrhythmic substrate in
patients with ischemic cardiomyopathy. However,
nephrotoxic effects of iodinated contrast and the occur-
rence of imaging artefacts resulting from metal devices
may hinder its use in some cardiomyopathy patients.
CONCLUSION
Advanced non-invasive imaging techniques such as
nuclear imaging, CMR, and CT have emerged during
the past decades to evaluate multiple aspects of the
substrate of VA. Typical imaging targets include
myocardial perfusion abnormalities, hibernation, scar,
scar border zone, and sympathetic innervation. Their
role in identifying the origin of VA has been shown in
multiple studies suggesting significant value in diagnosis
and risk assessment of VA, and a potential role in
guiding ablation strategies. For detecting perfusion
abnormalities, most experience has been gained using
SPECT and PET, whereas LGE-CMR is the preferred
modality for scar and border zone evaluation. More
biological aspects of the arrhythmic substrate such as
metabolism and sympathetic nerve function are well
performed using PET. As targets of multiple imaging
modalities may be intertwined, studies are warranted
that compare imaging parameters of the arrhythmic
substrate obtained by different modalities to define the
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Figure 11. Example of signal intensity map of the subendo-
cardial tissue projected onto a 3-dimensional endocardial shell
reconstruction of the left ventricle. Scar core area with high
signal intensity is presented in red, whereas normal myocar-
dium is presented in purple. Black and white arrows indicate
two corridors of continuous heterogeneous tissue with inter-
mediate signal intensity (green) surrounded by scar tissue. The
left upper corner shows the corresponding long-axis LGE-
CMR image with heterogeneous tissue located between the
mitral valve and the inferior scar (black arrowheads). CMR,
cardiovascular magnetic resonance imaging; LGE, late
gadolinium enhancement. Reprint with permission.102
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